Companies GeneDx Holdings Corp.
GeneDx (WGS): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me GeneDx Holdings Corp.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers91st pct.Of 11 peer CEOs
CEO pay, last three years
- $3,575,335FY2023
- $4,421,800FY2024
- $13,547,219FY2025
CEO total pay was $13,547,219 in fiscal 2025, up from $4,421,800 in fiscal 2024.
FY2025: salary $715,869 · bonus $0 · stock awards $11,738,600 · option awards $0
Executives and directors
Frequently asked questions
Who was the highest-paid executive at GeneDx Holdings Corp. in fiscal 2025?
As disclosed, Katherine Stueland (Chief Executive Officer) was the highest-paid executive at GeneDx Holdings Corp. in fiscal 2025, with total compensation of $13,547,219.
How does GeneDx Holdings Corp.'s chief executive pay compare to its disclosed peer group?
As disclosed, Katherine Stueland's total compensation ranked at the 91st percentile of GeneDx Holdings Corp.'s disclosed peer group.
How did shareholders vote on GeneDx Holdings Corp.'s executive compensation?
As disclosed, 93.91% of shareholders supported GeneDx Holdings Corp.'s executive compensation in the latest say-on-pay vote.
How much does GeneDx Holdings Corp. spend in total on board compensation for fiscal 2025?
As disclosed, GeneDx Holdings Corp. reported total board compensation of $2,256,576 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Katherine Stueland | $715,869 | $0 | $11,738,600 | $0 | $1,075,500 | $0 | $17,250 | $13,547,219 |
| Chief Executive Officer | ||||||||
| Kevin Feeley | 500,600 | 0 | 3,756,926 | 0 | 414,150 | 0 | 17,250 | 4,688,926 |
| Chief Financial Officer | ||||||||
| Bryan Dechairo | 436,154 | 75,000 | 2,699,971 | 0 | 371,250 | 0 | — | 3,582,375 |
| Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Katherine Stueland | $13,547,219 | $4,421,800 | $3,575,335 | ↑ +9,125,419 |
| Kevin Feeley | 4,688,926 | 1,349,600 | 1,574,227 | ↑ +3,339,326 |
| Bryan Dechairo | 3,582,375 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
GeneDx's executive compensation program is designed to attract, motivate, and retain highly qualified leaders who can execute the Company's growth strategy, advance innovation in genetic testing and diagnostics, and deliver sustainable long-term stockholder value.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Bryan Dechairo | RSU | 2025-01-14 | — | — | 37,497 | — | $2,699,971 |
| Katherine Stueland | RSU | 2025-03-15 | — | — | 47,684 | — | 4,695,443 |
| Kevin Feeley | PSU | 2025-03-15 | 6,105 | 7,631 | — | 15,261 | 2,254,175 |
| Kevin Feeley | RSU | 2025-03-15 | — | — | 15,261 | — | 1,502,751 |
| Katherine Stueland | PSU | 2025-03-15 | 19,074 | 23,842 | — | 47,684 | 7,043,165 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Bryan Dechairo | $2,699,971 | $0 | $0 | 0.0% |
| Katherine Stueland | 4,695,443 | 7,043,165 | 0 | 60.0% |
| Kevin Feeley | 1,502,751 | 2,254,175 | 0 | 60.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Kevin Feeley | RSU | 1,508 | — | $196,131 |
| Kevin Feeley | RSU | 2,152 | — | 279,889 |
| Kevin Feeley | Option | 2,616 | 72.6 | — |
| Kevin Feeley | Option | 3,737 | 32.67 | — |
| Kevin Feeley | PSU | 7,630 | — | 992,358 |
| Katherine Stueland | RSU | 7,748 | — | 1,007,705 |
| Kevin Feeley | RSU | 9,849 | — | 1,280,961 |
| Katherine Stueland | Option | 13,452 | 72.6 | — |
| Kevin Feeley | RSU | 15,261 | — | 1,984,846 |
| Katherine Stueland | RSU | 26,186 | — | 3,405,751 |
| Kevin Feeley | RSU | 35,984 | — | 4,680,079 |
| Bryan Dechairo | RSU | 37,497 | — | 2,699,971 |
| Katherine Stueland | RSU | 47,684 | — | 6,201,781 |
| Katherine Stueland | PSU | 47,684 | — | 6,201,781 |
| Kevin Feeley | RSU | 48,750 | — | 6,340,425 |
| Katherine Stueland | RSU | 93,750 | — | 12,193,125 |
| Katherine Stueland | RSU | 240,000 | — | 31,214,400 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Thomas FuchsIndependent · Partial-year service · Newly elected | $14,402 | $439,789 | $0 | $0 | $0 | $454,191 |
| Jason RyanNot independent · Board Chair · Not standing for re-election | 94,278 | 230,402 | 0 | 0 | 0 | 324,679 |
| Emily LeproustIndependent · Audit · Compensation · Nominating/Governance (Chair) · NOMINATING AND CORPORATE GOVERNANCE COMMITTEE (Chair) | 74,639 | 230,402 | 0 | 0 | 0 | 305,041 |
| Keith MeisterIndependent · Audit (Chair) · AUDIT COMMITTEE (Chair) | 67,139 | 230,402 | 0 | 0 | 0 | 297,541 |
| Joshua RuchIndependent · Compensation (Chair) · Nominating/Governance · COMPENSATION COMMITTEE (Chair) | 67,139 | 230,402 | 0 | 0 | 0 | 297,541 |
| Eli D. CasdinIndependent · Compensation · Nominating/Governance | 59,639 | 230,402 | 0 | 0 | 0 | 290,041 |
| Richard C. Pfenniger, JrIndependent · Audit | 57,139 | 230,402 | 0 | 0 | 0 | 287,541 |
| Katherine StuelandEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $338,480 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 10,000 / 7,500 / 5,000 |
| Stock ownership guideline | 300% of annual cash director retainer |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $434,375 |
| Equity awards (grant-date value) | $1,822,201 |
| All other compensation | $0 |
| Total cost of the board | $2,256,576 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names GeneDx as a peer
Companies that benchmark against WGS
6 companies name WGS as a compensation peer
- CASTLE BIOSCIENCES INCCSTLFY2025
- DocGo Inc.DCGOFY2025
- Fulgent Genetics, Inc.FLGTFY2025
- ILLUMINA, INC.ILMNFY2025
- Personalis, Inc.PSNLFY2025
- Tempus AI, Inc.TEMFY2025
Each company listed discloses WGS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named WGS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
CERS CerusNTRA NateraPACB Pacific Biosciences of CaliforniaCSTL Castle BiosciencesMIRM Mirum PharmaceuticalsTXG 10x GenomicsNEO NeoGenomicsLAB Standard BioToolsVCYT VeracyteCDNA CareDxAXGN Axogen
Peer reciprocity
The companies GeneDx Holdings Corp. names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Natera | 2025 | Steven Chapman | $853,710 | $12,979,558 | $0 | $1,114,151 | $14,957,319 |
| 2 | GeneDx Holdings Corp. | 2025 | Katherine Stueland | 715,869 | 11,738,600 | 0 | 1,075,500 | 13,547,219 |
| 3 | Mirum Pharmaceuticals | 2025 | Christopher Peetz | 755,000 | 3,683,904 | 4,931,320 | 1,057,000 | 10,441,224 |
| 4 | NeoGenomics | 2025 | Tony Zook | 601,539 | 3,999,997 | 3,998,235 | 513,400 | 9,127,092 |
| 5 | Axogen | 2025 | Michael Dale | 775,865 | 7,342,895 | 0 | 906,133 | 9,047,454 |
| 6 | Standard BioTools | 2025 | Michael Egholm | 680,256 | 5,337,883 | 1,671,363 | 1,120,000 | 8,823,502 |
| 7 | Veracyte | 2025 | Marc Stapley | 700,000 | 5,890,877 | 0 | 826,000 | 7,421,877 |
| 8 | CareDx | 2025 | John Hanna | 693,269 | 5,622,638 | 0 | 852,515 | 7,179,699 |
| 9 | Castle Biosciences | 2025 | Derek Maetzold | 751,350 | 4,977,208 | 0 | 1,036,863 | 6,786,771 |
| 10 | 10x Genomics | 2025 | Serge Saxonov | 674,250 | 5,020,269 | 0 | 634,725 | 6,329,244 |
| 11 | Pacific Biosciences of California | 2025 | Christian Henry | 748,250 | 1,151,013 | 1,696,278 | 714,305 | 4,309,846 |
| 12 | Cerus | 2025 | William Greenman | 793,750 | 2,242,585 | 0 | 756,000 | 3,794,657 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| GeneDx Holdings Corp. | 150% | PSU 50 · RSU 50 | No | Pearl Meyer |
| 10x Genomics | 93% | PSU 60 · RSU 40 | Yes — 3-year Relative TSR | Alpine Rewards LLC |
| Axogen | 116.79% | PSU 50 · RSU 50 | No | Aon |
| CareDx | not disclosed | RSU 70 · PRSU 30 | No | Alpine Rewards |
| Castle Biosciences | 138% | RSU 50 · PSU 50 | No | AON (AON's Human Capital Solutions Practice, a division of AON plc) |
| Cerus | 126% | not disclosed | No | Alpine |
| Mirum Pharmaceuticals | 200% | Option 47.2 · PSU 17.6 · RSU 17.6 | No | Alpine Rewards |
| Natera | 131.1% | PSU 50 · RSU 50 | No | Aon |
| NeoGenomics | 60% | RSU 50 · Options 50 | not disclosed | WTW |
| Pacific Biosciences of California | 95% | not disclosed | not disclosed | Aon Human Capital Solutions |
| Standard BioTools | 160% | not disclosed | not disclosed | Pearl Meyer |
| Veracyte | 118% | PSU 50 · RSU 50 | No | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-18 | 22,705,946 | 1,471,593 | 41,821 | 93.91% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-18 | 93.91%a |
a. Approved under the standard stated in the filing — “At the Annual Meeting, abstentions will have no effect on Proposal No.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Keith Meister | Director | 2026-05-07 | A | 128,181 | $35 | $4,545,298 | Common, indirect | Form 4 ↗ |
| Casdin Capital, LLC | Director | 2026-05-07 | A | 500,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Keith Meister | Director | 2026-05-07 | A | 56,630 | 40 | 2,291,250 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-07 | A | 94,356 | 39 | 3,716,683 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-07 | A | 116,412 | 38 | 4,477,206 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-07 | A | 14,786 | 36 | 537,175 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-07 | A | 123,393 | 38 | 4,639,577 | Common, indirect | Form 4 ↗ |
| Casdin Capital, LLC | Director | 2026-05-08 | A | 300,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Keith Meister | Director | 2026-05-08 | A | 3,396 | 39 | 131,425 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-08 | A | 73,104 | 41 | 3,008,230 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-08 | A | 79,144 | 41 | 3,218,786 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-08 | A | 15,745 | 38 | 598,310 | Common, indirect | Form 4 ↗ |
| Casdin Capital, LLC | Director | 2026-05-11 | A | 50,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Keith Meister | Director | 2026-05-11 | A | 532 | 40 | 21,466 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-11 | A | 252,734 | 40 | 10,020,903 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-11 | A | 246,734 | 39 | 9,600,420 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-13 | A | 70,926 | 39 | 2,798,031 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-13 | A | 94,074 | 39 | 3,651,953 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-14 | A | 51,893 | 40 | 2,071,569 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-14 | A | 88,107 | 39 | 3,443,222 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-15 | A | 27,408 | 38 | 1,049,178 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-15 | A | 18,865 | 40 | 751,393 | Common, indirect | Form 4 ↗ |
| Casdin Capital, LLC | Director | 2026-05-18 | A | 175,000 | 43 | 7,446,548 | Common | Form 4 ↗ |
| Casdin Capital, LLC | Director | 2026-05-19 | A | 185,000 | 43 | 7,880,334 | Common | Form 4 ↗ |
| Casdin Capital, LLC | Director | 2026-05-20 | A | 140,000 | 44 | 6,132,854 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-01 | — | 717 | — | — | 1 insider, 1 accrual row | ||
| Kevin Feeley | Chief Financial Officer | 2026-06-01 | D | 369 | 52 | 19,092 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-06-01 | A | 717 | 0 | 0 | Common | Form 4 ↗ |
| Casdin Capital, LLC | Director | 2026-06-04 | A | 150,000 | 56 | 8,466,735 | Common | Form 4 ↗ |
| Casdin Capital, LLC | Director | 2026-06-05 | A | 50,000 | 53 | 2,642,830 | Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-06-09 | D | 6,546 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-06-09 | D | 3,639 | 54 | 195,669 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-06-09 | D | 2,462 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-06-09 | A | 6,546 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-06-09 | D | 1,266 | 54 | 68,073 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-06-09 | A | 2,462 | 0 | 0 | Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-06-16 | D | 5,932 | 61 | 360,838 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-06-16 | D | 863 | 62 | 53,078 | Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-06-16 | D | 2,140 | 60 | 127,874 | Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-06-16 | D | 18,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-06-16 | D | 2,429 | 62 | 149,392 | Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-06-16 | A | 18,750 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-06-16 | D | 2,106 | 61 | 128,106 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-06-16 | D | 7,197 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-06-16 | D | 760 | 60 | 45,413 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-06-16 | A | 7,197 | 0 | 0 | Common | Form 4 ↗ |
| Emily Leproust | Director | 2026-06-18 | D | 3,576 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eli D. Casdin | Director | 2026-06-18 | D | 3,576 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas Fuchs | Director | 2026-06-18 | A | 4,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Keith Meister | Director | 2026-06-18 | D | 3,576 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Keith Meister | Director | 2026-06-18 | A | 3,576 | 0 | 0 | Common | Form 4 ↗ |
| Richard C. Pfenniger, Jr | Director | 2026-06-18 | A | 4,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard C. Pfenniger, Jr | Director | 2026-06-18 | A | 3,576 | 0 | 0 | Common | Form 4 ↗ |
| Joshua Ruch | Director | 2026-06-18 | D | 3,576 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joshua Ruch | Director | 2026-06-18 | A | 3,576 | 0 | 0 | Common | Form 4 ↗ |
| Joshua Ruch | Director | 2026-06-18 | A | 4,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jason Ryan | Director | 2026-06-18 | D | 3,576 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jason Ryan | Director | 2026-06-18 | A | 3,576 | 0 | 0 | Common | Form 4 ↗ |
| Emily Leproust | Director | 2026-06-18 | A | 3,576 | 0 | 0 | Common | Form 4 ↗ |
| Richard C. Pfenniger, Jr | Director | 2026-06-18 | D | 3,576 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eli D. Casdin | Director | 2026-06-18 | A | 4,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eli D. Casdin | Director | 2026-06-18 | A | 3,576 | 0 | 0 | Common | Form 4 ↗ |
| Keith Meister | Director | 2026-06-18 | A | 4,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Emily Leproust | Director | 2026-06-18 | A | 4,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark A. Gardner | President | 2026-06-29 | A | 35,441 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-09-01 | — | 717 | — | — | 1 insider, 1 accrual row | ||
| Kevin Feeley | Chief Financial Officer | 2026-09-01 | D | 372 | 84 | 31,188 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-09-01 | A | 717 | 0 | 0 | Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-09-09 | A | 6,547 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-09-09 | D | 2,462 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-09-09 | D | 1,285 | 84 | 108,220 | Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-09-09 | D | 6,547 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-09-09 | D | 3,692 | 84 | 310,932 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-09-09 | A | 2,462 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-09-16 | D | 7,197 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-09-16 | D | 1,470 | 98 | 144,457 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-09-16 | D | 541 | 97 | 52,423 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-09-16 | D | 586 | 94 | 55,235 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-09-16 | A | 7,197 | 0 | 0 | Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-09-16 | D | 18,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-09-16 | D | 3,039 | 99 | 300,846 | Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-09-16 | D | 4,141 | 98 | 406,936 | Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-09-16 | D | 1,525 | 97 | 147,774 | Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-09-16 | D | 148 | 95 | 14,120 | Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-09-16 | D | 1,648 | 94 | 155,337 | Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-09-16 | A | 18,750 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-09-16 | D | 1,079 | 99 | 106,816 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-09-16 | D | 52 | 95 | 4,961 | Common | Form 4 ↗ |
| Thomas Fuchs | Director | 2026-09-17 | A | 1,146 | 0 | 0 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-09-17 | — | 1,146 | — | — | 1 insider, 1 accrual row | ||
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 90 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Keith Meister | Director | 2026-05-07 | A | 128,181 | $35 | $4,545,298 | Common, indirect | Form 4 ↗ |
| Casdin Capital, LLC | Director | 2026-05-07 | A | 500,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Keith Meister | Director | 2026-05-07 | A | 56,630 | 40 | 2,291,250 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-07 | A | 94,356 | 39 | 3,716,683 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-07 | A | 116,412 | 38 | 4,477,206 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-07 | A | 14,786 | 36 | 537,175 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-07 | A | 123,393 | 38 | 4,639,577 | Common, indirect | Form 4 ↗ |
| Casdin Capital, LLC | Director | 2026-05-08 | A | 300,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Keith Meister | Director | 2026-05-08 | A | 3,396 | 39 | 131,425 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-08 | A | 73,104 | 41 | 3,008,230 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-08 | A | 79,144 | 41 | 3,218,786 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-08 | A | 15,745 | 38 | 598,310 | Common, indirect | Form 4 ↗ |
| Casdin Capital, LLC | Director | 2026-05-11 | A | 50,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Keith Meister | Director | 2026-05-11 | A | 532 | 40 | 21,466 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-11 | A | 252,734 | 40 | 10,020,903 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-11 | A | 246,734 | 39 | 9,600,420 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-13 | A | 70,926 | 39 | 2,798,031 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-13 | A | 94,074 | 39 | 3,651,953 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-14 | A | 51,893 | 40 | 2,071,569 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-14 | A | 88,107 | 39 | 3,443,222 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-15 | A | 27,408 | 38 | 1,049,178 | Common, indirect | Form 4 ↗ |
| Keith Meister | Director | 2026-05-15 | A | 18,865 | 40 | 751,393 | Common, indirect | Form 4 ↗ |
| Casdin Capital, LLC | Director | 2026-05-18 | A | 175,000 | 43 | 7,446,548 | Common | Form 4 ↗ |
| Casdin Capital, LLC | Director | 2026-05-19 | A | 185,000 | 43 | 7,880,334 | Common | Form 4 ↗ |
| Casdin Capital, LLC | Director | 2026-05-20 | A | 140,000 | 44 | 6,132,854 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-06-01 | D | 717 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-06-01 | D | 369 | 52 | 19,092 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-06-01 | A | 717 | 0 | 0 | Common | Form 4 ↗ |
| Casdin Capital, LLC | Director | 2026-06-04 | A | 150,000 | 56 | 8,466,735 | Common | Form 4 ↗ |
| Casdin Capital, LLC | Director | 2026-06-05 | A | 50,000 | 53 | 2,642,830 | Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-06-09 | D | 6,546 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-06-09 | D | 3,639 | 54 | 195,669 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-06-09 | D | 2,462 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-06-09 | A | 6,546 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-06-09 | D | 1,266 | 54 | 68,073 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-06-09 | A | 2,462 | 0 | 0 | Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-06-16 | D | 5,932 | 61 | 360,838 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-06-16 | D | 863 | 62 | 53,078 | Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-06-16 | D | 2,140 | 60 | 127,874 | Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-06-16 | D | 18,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-06-16 | D | 2,429 | 62 | 149,392 | Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-06-16 | A | 18,750 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-06-16 | D | 2,106 | 61 | 128,106 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-06-16 | D | 7,197 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-06-16 | D | 760 | 60 | 45,413 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-06-16 | A | 7,197 | 0 | 0 | Common | Form 4 ↗ |
| Emily Leproust | Director | 2026-06-18 | D | 3,576 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eli D. Casdin | Director | 2026-06-18 | D | 3,576 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas Fuchs | Director | 2026-06-18 | A | 4,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Keith Meister | Director | 2026-06-18 | D | 3,576 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Keith Meister | Director | 2026-06-18 | A | 3,576 | 0 | 0 | Common | Form 4 ↗ |
| Richard C. Pfenniger, Jr | Director | 2026-06-18 | A | 4,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard C. Pfenniger, Jr | Director | 2026-06-18 | A | 3,576 | 0 | 0 | Common | Form 4 ↗ |
| Joshua Ruch | Director | 2026-06-18 | D | 3,576 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joshua Ruch | Director | 2026-06-18 | A | 3,576 | 0 | 0 | Common | Form 4 ↗ |
| Joshua Ruch | Director | 2026-06-18 | A | 4,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jason Ryan | Director | 2026-06-18 | D | 3,576 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jason Ryan | Director | 2026-06-18 | A | 3,576 | 0 | 0 | Common | Form 4 ↗ |
| Emily Leproust | Director | 2026-06-18 | A | 3,576 | 0 | 0 | Common | Form 4 ↗ |
| Richard C. Pfenniger, Jr | Director | 2026-06-18 | D | 3,576 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eli D. Casdin | Director | 2026-06-18 | A | 4,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eli D. Casdin | Director | 2026-06-18 | A | 3,576 | 0 | 0 | Common | Form 4 ↗ |
| Keith Meister | Director | 2026-06-18 | A | 4,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Emily Leproust | Director | 2026-06-18 | A | 4,248 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark A. Gardner | President | 2026-06-29 | A | 35,441 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-09-01 | D | 717 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-09-01 | D | 372 | 84 | 31,188 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-09-01 | A | 717 | 0 | 0 | Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-09-09 | A | 6,547 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-09-09 | D | 2,462 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-09-09 | D | 1,285 | 84 | 108,220 | Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-09-09 | D | 6,547 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-09-09 | D | 3,692 | 84 | 310,932 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-09-09 | A | 2,462 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-09-16 | D | 7,197 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-09-16 | D | 1,470 | 98 | 144,457 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-09-16 | D | 541 | 97 | 52,423 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-09-16 | D | 586 | 94 | 55,235 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-09-16 | A | 7,197 | 0 | 0 | Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-09-16 | D | 18,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-09-16 | D | 3,039 | 99 | 300,846 | Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-09-16 | D | 4,141 | 98 | 406,936 | Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-09-16 | D | 1,525 | 97 | 147,774 | Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-09-16 | D | 148 | 95 | 14,120 | Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-09-16 | D | 1,648 | 94 | 155,337 | Common | Form 4 ↗ |
| Katherine Stueland | Director | 2026-09-16 | A | 18,750 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-09-16 | D | 1,079 | 99 | 106,816 | Common | Form 4 ↗ |
| Kevin Feeley | Chief Financial Officer | 2026-09-16 | D | 52 | 95 | 4,961 | Common | Form 4 ↗ |
| Thomas Fuchs | Director | 2026-09-17 | A | 1,146 | 0 | 0 | Common | Form 4 ↗ |
| Thomas Fuchs | Director | 2026-09-17 | D | 1,146 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Sources (124 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Katherine Stueland. DEF 14A, filed 2026-04-30. Section “2025 SUMMARY COMPENSATION TABLE” · page 37. As printed: 13,547,219. View filing ↗
- Section 01, Kevin Feeley. DEF 14A, filed 2026-04-30. Section “2025 SUMMARY COMPENSATION TABLE”. As printed: 4,688,926. View filing ↗
- Section 01, Bryan Dechairo. DEF 14A, filed 2026-04-30. Section “2025 SUMMARY COMPENSATION TABLE”. As printed: 3,582,375. View filing ↗
- Section 03, Bryan Dechairo RSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Katherine Stueland RSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Kevin Feeley PSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Kevin Feeley RSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Katherine Stueland PSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-30. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Thomas Fuchs. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 454,191. View filing ↗
- Section 08, Jason Ryan. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 324,679. View filing ↗
- Section 08, Emily Leproust. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 305,041. View filing ↗
- Section 08, Keith Meister. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 297,541. View filing ↗
- Section 08, Joshua Ruch. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 297,541. View filing ↗
- Section 08, Eli D. Casdin. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 290,041. View filing ↗
- Section 08, Richard C. Pfenniger, Jr. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 287,541. View filing ↗
- Section 08, Katherine Stueland. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Keith Meister 2026-05-07. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Casdin Capital, LLC 2026-05-07. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Keith Meister 2026-05-07. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Keith Meister 2026-05-07. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Keith Meister 2026-05-07. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Keith Meister 2026-05-07. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Keith Meister 2026-05-07. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Casdin Capital, LLC 2026-05-08. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Keith Meister 2026-05-08. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Keith Meister 2026-05-08. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Keith Meister 2026-05-08. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Keith Meister 2026-05-08. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Casdin Capital, LLC 2026-05-11. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Keith Meister 2026-05-11. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Keith Meister 2026-05-11. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Keith Meister 2026-05-11. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Keith Meister 2026-05-13. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Keith Meister 2026-05-13. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Keith Meister 2026-05-14. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Keith Meister 2026-05-14. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Keith Meister 2026-05-15. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Keith Meister 2026-05-15. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Casdin Capital, LLC 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Casdin Capital, LLC 2026-05-19. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Casdin Capital, LLC 2026-05-20. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Feeley 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Feeley 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Feeley 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Casdin Capital, LLC 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Casdin Capital, LLC 2026-06-05. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katherine Stueland 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katherine Stueland 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Feeley 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katherine Stueland 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Feeley 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Feeley 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katherine Stueland 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Feeley 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katherine Stueland 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katherine Stueland 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katherine Stueland 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katherine Stueland 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Feeley 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Feeley 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Feeley 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Feeley 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Emily Leproust 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eli D. Casdin 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Fuchs 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Keith Meister 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Keith Meister 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard C. Pfenniger, Jr 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard C. Pfenniger, Jr 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joshua Ruch 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joshua Ruch 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joshua Ruch 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Ryan 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Ryan 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Emily Leproust 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard C. Pfenniger, Jr 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eli D. Casdin 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eli D. Casdin 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Keith Meister 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Emily Leproust 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark A. Gardner 2026-06-29. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Feeley 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Feeley 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Feeley 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katherine Stueland 2026-09-09. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Feeley 2026-09-09. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Feeley 2026-09-09. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katherine Stueland 2026-09-09. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katherine Stueland 2026-09-09. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Feeley 2026-09-09. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Feeley 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Feeley 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Feeley 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Feeley 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Feeley 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katherine Stueland 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katherine Stueland 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katherine Stueland 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katherine Stueland 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katherine Stueland 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katherine Stueland 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katherine Stueland 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Feeley 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Feeley 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Fuchs 2026-09-17. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Fuchs 2026-09-17. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-23. Item 5.07 · say-on-pay result. As reported: 93.91% (votes for as printed: 22,705,946). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 434,375 + equity 1,822,201 + all other 0 = 2,256,576, summed across the director compensation table rows.
- Natera, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Natera's own proxy. As printed: 14,957,319. View filing ↗
- GeneDx Holdings Corp. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in GeneDx Holdings Corp.'s own proxy. As printed: 13,547,219. View filing ↗
- Mirum Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Mirum Pharmaceuticals's own proxy. As printed: 10,441,224. View filing ↗
- NeoGenomics, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in NeoGenomics's own proxy. As printed: 9,127,092. View filing ↗
- Axogen, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Axogen's own proxy. As printed: 9,047,454. View filing ↗
- Standard BioTools, Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Standard BioTools's own proxy. As printed: 8,823,502. View filing ↗
- Veracyte, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Veracyte's own proxy. As printed: 7,421,877. View filing ↗
- CareDx, Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in CareDx's own proxy. As printed: 7,179,699. View filing ↗
- Castle Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Castle Biosciences's own proxy. As printed: 6,786,771. View filing ↗
- 10x Genomics, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in 10x Genomics's own proxy. As printed: 6,329,244. View filing ↗
- Pacific Biosciences of California, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Pacific Biosciences of California's own proxy. As printed: 4,309,846. View filing ↗
- Cerus, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Cerus's own proxy. As printed: 3,794,657. View filing ↗
- Section 10a, Castle Biosciences reciprocity. DEF 14A. Castle Biosciences names GeneDx Holdings Corp. in its own disclosed peer group (read from its most recent proxy). View filing ↗